77,266 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by Integrated Quantitative Investments LLC

Integrated Quantitative Investments LLC bought a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 77,266 shares of the biotechnology company’s stock, valued at approximately $1,325,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. National Bank of Canada FI purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $35,000. GAMMA Investing LLC grew its position in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 967 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new stake in ADMA Biologics during the fourth quarter valued at approximately $35,000. Vision Financial Markets LLC bought a new position in ADMA Biologics in the fourth quarter worth approximately $51,000. Finally, AlphaQuest LLC purchased a new position in shares of ADMA Biologics during the 4th quarter worth $84,000. 75.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA opened at $19.45 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1 year low of $5.90 and a 1 year high of $23.64. The firm has a fifty day moving average price of $17.41 and a 200-day moving average price of $18.20. The stock has a market cap of $4.60 billion, a PE ratio of 69.46 and a beta of 0.60.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.